Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 OrganiGramAlbireo PharmaAkouosAtrecaIntercept Pharmaceuticals
SymbolNASDAQ:OGINASDAQ:ALBONASDAQ:AKUSNASDAQ:BCELNASDAQ:ICPT
Price Information
Current Price$2.77$31.94$14.51$11.48$22.14
52 Week RangeHoldBuyBuyBuyHold
MarketRank™
Overall Score1.61.51.61.72.2
Analysis Score4.23.53.43.54.1
Community Score3.02.52.52.73.1
Dividend Score0.00.00.00.00.0
Ownership Score0.01.71.71.73.3
Earnings & Valuation Score0.60.00.60.60.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyHold
Consensus Price Target$4.60$72.00$31.67$29.00$50.70
% Upside from Price Target66.02% upside125.42% upside118.24% upside152.61% upside128.98% upside
Trade Information
Market Cap$643.39 million$610.50 million$499.17 million$422.82 million$730.97 million
Beta0.31.62N/A0.081.85
Average Volume24,492,986172,677220,302261,1101,107,927
Sales & Book Value
Annual Revenue$64.61 million$9.64 millionN/AN/A$252 million
Price / Sales9.9663.33N/AN/A2.90
Cashflow$0.03 per shareN/AN/AN/AN/A
Price / Cash101.50N/AN/AN/AN/A
Book Value$1.04 per share$7.34 per shareN/A$6.68 per share$1.57 per share
Price / Book2.664.35N/AN/A14.10
Profitability
Net Income$-101,290,000.00$-62,720,000.00N/A$-67,480,000.00$-344,680,000.00
EPS($0.08)($5.04)N/A($4.26)($10.89)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-207.26%-751.53%N/AN/A-106.64%
Return on Equity (ROE)-10.00%-71.22%N/A-43.21%-1,973.10%
Return on Assets (ROA)-7.14%-42.91%N/A-40.98%-48.51%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.17%0.04%N/AN/AN/A
Current Ratio2.66%13.52%37.39%28.48%3.44%
Quick Ratio3.39%13.51%37.39%28.48%3.44%
Ownership Information
Institutional Ownership Percentage10.84%85.65%88.70%69.64%85.77%
Insider Ownership PercentageN/A5.00%N/A9.90%23.70%
Miscellaneous
Employees5169054130498
Shares Outstanding232.27 million19.11 million34.40 million36.83 million33.02 million
Next Earnings Date4/13/2021 (Confirmed)5/6/2021 (Estimated)7/5/2021 (Estimated)5/13/2021 (Estimated)5/10/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
Small Cap Stock Intercept Pharmaceuticals, Inc. (ICPT) is a Overweight – AnalystsSmall Cap Stock Intercept Pharmaceuticals, Inc. (ICPT) is a Overweight – Analysts
marketingsentinel.com - April 12 at 3:01 PM
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average Rating of "Hold" from BrokeragesIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Receives Average Rating of "Hold" from Brokerages
americanbankingnews.com - April 4 at 4:36 AM
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is Worth a Shot if You’re a Risk-Capital InvestorIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is Worth a Shot if You’re a Risk-Capital Investor
marketingsentinel.com - March 29 at 2:04 PM
Intercept Pharmaceuticals Stock Is Believed To Be Possible Value TrapIntercept Pharmaceuticals Stock Is Believed To Be Possible Value Trap
finance.yahoo.com - March 28 at 1:57 AM
Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - March 27 at 2:48 PM
What Did We Learn From Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Trading?What Did We Learn From Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Trading?
stocksregister.com - March 26 at 1:42 PM
Intercept Pharmaceuticals Inc. [ICPT] Stock trading around $24.88 per share: What’s Next?Intercept Pharmaceuticals Inc. [ICPT] Stock trading around $24.88 per share: What’s Next?
dbtnews.com - March 26 at 8:42 AM
Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Price Up 7.2%Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Price Up 7.2%
americanbankingnews.com - March 25 at 11:37 AM
3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall Street3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall Street
finance.yahoo.com - March 23 at 3:52 AM
Intercept Pharmaceuticals (NASDAQ:ICPT) Stock Rating Upgraded by HC WainwrightIntercept Pharmaceuticals (NASDAQ:ICPT) Stock Rating Upgraded by HC Wainwright
americanbankingnews.com - March 18 at 10:12 AM
Intercept Pharmaceuticals (NASDAQ:ICPT) Raised to Neutral at HC WainwrightIntercept Pharmaceuticals (NASDAQ:ICPT) Raised to Neutral at HC Wainwright
marketbeat.com - March 18 at 8:35 AM
Biotechnology Stocks Giving Back Ground After Yesterdays RallyBiotechnology Stocks Giving Back Ground After Yesterday's Rally
nasdaq.com - March 16 at 5:02 PM
Monday 3/15 Insider Buying Report: ICPT, DBXMonday 3/15 Insider Buying Report: ICPT, DBX
nasdaq.com - March 15 at 3:56 PM
Intercept Announces Departure of Chief Financial OfficerIntercept Announces Departure of Chief Financial Officer
finance.yahoo.com - March 10 at 8:09 AM
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Just Reported Earnings, And Analysts Cut Their Target PriceIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Just Reported Earnings, And Analysts Cut Their Target Price
nasdaq.com - February 28 at 1:15 PM
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2020 Results - Earnings Call TranscriptIntercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 26 at 6:44 PM
Intercepts (ICPT) Q4 Loss Wider than Expected, Sales MissIntercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss
finance.yahoo.com - February 26 at 1:44 PM
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues ...Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues ...
apnews.com - February 25 at 9:53 AM
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Misses Revenue EstimatesIntercept Pharmaceuticals (ICPT) Reports Q4 Loss, Misses Revenue Estimates
nasdaq.com - February 25 at 9:53 AM
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business UpdateIntercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update
finance.yahoo.com - February 25 at 9:53 AM
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Long Term Investor Alert: Investigation of Potential WrongdoingIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Long Term Investor Alert: Investigation of Potential Wrongdoing
sbwire.com - February 24 at 1:44 PM
Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of DirectorsIntercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors
marketwatch.com - February 23 at 9:16 AM
Intercept to Present at Upcoming Investor ConferencesIntercept to Present at Upcoming Investor Conferences
finance.yahoo.com - February 19 at 10:26 AM
Investigation announced for Long-Term Investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)Investigation announced for Long-Term Investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
openpr.com - February 19 at 5:26 AM
Avadel Pharmaceuticals Appoints Richard Kim As CCO; Says He Will Lead Launch Of Once-Nightly FT218, Pending Regulatory ApprovalAvadel Pharmaceuticals Appoints Richard Kim As CCO; Says He Will Lead Launch Of Once-Nightly FT218, Pending Regulatory Approval
benzinga.com - February 17 at 3:05 PM
Intercept Appoints Linda Richardson as Chief Commercial OfficerIntercept Appoints Linda Richardson as Chief Commercial Officer
markets.businessinsider.com - February 17 at 9:03 AM
DateCompanyBrokerageAction
4/8/2021OrganiGramBMO Capital MarketsUpgrade
3/16/2021OrganiGramStifel NicolausBoost Price Target
3/12/2021OrganiGramCIBCBoost Price Target
3/12/2021OrganiGramRaymond JamesBoost Price Target
3/11/2021OrganiGramCantor FitzgeraldReiterated Rating
3/11/2021OrganiGramAlliance Global PartnersReiterated Rating
1/12/2021OrganiGramCanaccord GenuityDowngrade
8/10/2020OrganiGramJefferies Financial GroupReiterated Rating
7/21/2020OrganiGramPi FinancialReiterated Rating
7/21/2020OrganiGramAltaCorp CapitalDowngrade
7/21/2020OrganiGramOppenheimerReiterated Rating
3/8/2021Albireo PharmaPiper SandlerBoost Price Target
3/1/2021Albireo PharmaRobert W. BairdReiterated Rating
12/18/2020Albireo PharmaHC WainwrightBoost Price Target
11/19/2020Albireo PharmaWedbushReiterated Rating
9/10/2020Albireo PharmaCowenBoost Price Target
9/8/2020Albireo PharmaNeedham & Company LLCBoost Price Target
8/10/2020Albireo PharmaWilliam BlairReiterated Rating
3/30/2021AkouosBank of AmericaDowngrade
7/21/2020AkouosBTIG ResearchInitiated Coverage
9/4/2019AtrecaRoth CapitalInitiated Coverage
8/20/2019AtrecaBrookline Capital ManagementReiterated Rating
7/15/2019AtrecaEvercore ISIInitiated Coverage
3/1/2021Intercept PharmaceuticalsB. RileyLower Price Target
3/1/2021Intercept PharmaceuticalsChardan CapitalLower Price Target
11/10/2020Intercept PharmaceuticalsRoyal Bank of CanadaLower Price Target
11/10/2020Intercept PharmaceuticalsCredit Suisse GroupLower Price Target
11/10/2020Intercept PharmaceuticalsSVB LeerinkLower Price Target
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.